Fig. 3
From: Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome
Median overall survival based on the proliferation rate. Neuroendocrine neoplasms were distributed based on their proliferation rate: < 5%, 5–20%, > 20–55 and > 55%. Regarding median overall survival from initial diagnosis, there was no significant result after within the G3 neoplasms (Ki-67 > 20–55% vs. > 55%, 19 vs. 28 months; P = 0.91) (a). However, after BM detection the proliferation rate was associated with a worsened outcome (15, 13, 9 and 7 months), although statistical significance was not reached (P = 0.14) (b)